Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma

Pseudoprogression (PsPr) after concurrent radiotherapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma multiforme (GBM)

(2017) J. L. Clarke et al.   JOURNAL OF CLINICAL ONCOLOGY

Pseudoprogression Following Chemoradiotherapy for Glioblastoma Multiforme

(2014) Paul Sanghera et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Potential for Differentiation of Pseudoprogression From True Tumor Progression With Dynamic Susceptibility-Weighted Contrast-Enhanced Magnetic Resonance Imaging Using Ferumoxytol vs. Gadoteridol: A Pilot Study

(2010) Seymur Gahramanov et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Parametric Response Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma

(2010) Christina Tsien et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Changes in Relative Cerebral Blood Volume 1 Month after Radiation-Temozolomide Therapy Can Help Predict Overall Survival in Patients with Glioblastoma

(2010) Rajiv Mangla et al.   RADIOLOGY

MR Spectroscopy in Radiation Injury

(2009) P.C. Sundgren   AMERICAN JOURNAL OF NEURORADIOLOGY

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH

Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging

(2009) Jennifer L. Clarke et al.   Current Neurology and Neuroscience Reports

Pseudoprogression and pseudoresponse in the treatment of gliomas

(2009) Dieta Brandsma et al.   CURRENT OPINION IN NEUROLOGY

Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation WithMGMTPromoter Methylation Status

(2009) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression

(2009) Elizabeth R. Gerstner et al.   JOURNAL OF NEURO-ONCOLOGY

VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer

(2009) Elizabeth R. Gerstner et al.   Nature Reviews Clinical Oncology

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment

(2009) Whitney B. Pope et al.   RADIOLOGY

Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations

(2009) Cristo Chaskis et al.   SURGICAL NEUROLOGY

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

(2008) Walter Taal et al.   CANCER

Pseudoprogression in Glioblastoma

(2008) Marc C. Chamberlain   JOURNAL OF CLINICAL ONCOLOGY

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology

(2008) Alba A. Brandes et al.   NEURO-ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Response criteria for glioma

(2008) A Gregory Sorensen et al.   Nature clinical practice. Oncology